Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Since the relapse rate of DLBCL to frontline chemoimmunotherapy and salvage autologous hematopoietic cell transplant is high, CD19-directed chimeric antigen receptor (CAR) T-cell therapy was adopted. Given the tim...

Descripción completa

Detalles Bibliográficos
Autores principales: Saifi, Omran, Kharfan-Dabaja, Mohamed A., Zeidan, Youssef H., Peterson, Jennifer, Rule, William G., Lester, Scott C., Hoppe, Bradford S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Particle Therapy Co-operative Group 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574825/
https://www.ncbi.nlm.nih.gov/pubmed/33094131
http://dx.doi.org/10.14338/IJPT-20-00004.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574825/
https://www.ncbi.nlm.nih.gov/pubmed/33094131
http://dx.doi.org/10.14338/IJPT-20-00004.1

Ejemplares similares